Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Lancet Oncol

Retrieve available abstracts of 67 articles:
HTML format
Text format



Single Articles


    May 2017
  1. DAS M
    Brigatinib effective in ALK-positive non-small-cell lung cancer.
    Lancet Oncol. 2017 May 11. pii: S1470-2045(17)30342.
    PubMed     Text format    


    March 2017
  2. GULLEY JL, Rajan A, Spigel DR, Iannotti N, et al
    Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
    Lancet Oncol. 2017 Mar 31. pii: S1470-2045(17)30240.
    PubMed     Text format     Abstract available


  3. TAKAHASHI T, Yamanaka T, Seto T, Harada H, et al
    Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30230.
    PubMed     Text format     Abstract available


  4. SLOTMAN BJ
    Time to reconsider prophylactic cranial irradiation in extensive-stage small-cell lung cancer?
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30193.
    PubMed     Text format    


  5. BROWER V
    Pravastatin has no advantage in small-cell lung cancer.
    Lancet Oncol. 2017 Mar 9. pii: S1470-2045(17)30184.
    PubMed     Text format    


    January 2017
  6. BURKI TK
    Treatment options not taken for non-small-cell lung cancer.
    Lancet Oncol. 2017 Jan 27. pii: S1470-2045(17)30066.
    PubMed     Text format    


  7. MAYOR S
    Osimertinib effective in EGFR T790M-positive lung cancer.
    Lancet Oncol. 2017;18:e9.
    PubMed     Text format    


    December 2016
  8. BROWER V
    Onartuzumab ineffective in non-small-cell lung cancer.
    Lancet Oncol. 2016 Dec 22. pii: S1470-2045(16)30680.
    PubMed     Text format    


  9. RUDIN CM, Pietanza MC, Bauer TM, Ready N, et al
    Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
    Lancet Oncol. 2016 Dec 2. pii: S1470-2045(16)30565.
    PubMed     Text format     Abstract available


  10. HELLMANN MD, Rizvi NA, Goldman JW, Gettinger SN, et al
    Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
    Lancet Oncol. 2016 Dec 2. pii: S1470-2045(16)30624.
    PubMed     Text format     Abstract available


  11. LIN JJ, Shaw AT
    Raising the bar on first-line immunotherapy in lung cancer.
    Lancet Oncol. 2016 Dec 2. pii: S1470-2045(16)30594.
    PubMed     Text format    


  12. ROSSI A
    Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancer.
    Lancet Oncol. 2016 Dec 2. pii: S1470-2045(16)30575.
    PubMed     Text format    


    November 2016
  13. GADGEEL SM
    Drug selection for anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Lancet Oncol. 2016 Nov 7. pii: S1470-2045(16)30567.
    PubMed     Text format    


  14. GETTINGER SN, Bazhenova LA, Langer CJ, Salgia R, et al
    Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Lancet Oncol. 2016 Nov 7. pii: S1470-2045(16)30392.
    PubMed     Text format     Abstract available


  15. NEAL JW, Dahlberg SE, Wakelee HA, Aisner SC, et al
    Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
    Lancet Oncol. 2016 Nov 4. pii: S1470-2045(16)30561.
    PubMed     Text format     Abstract available


  16. ROSELL R, Karachaliou N
    RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer.
    Lancet Oncol. 2016 Nov 4. pii: S1470-2045(16)30557.
    PubMed     Text format    


  17. DRILON A, Rekhtman N, Arcila M, Wang L, et al
    Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
    Lancet Oncol. 2016 Nov 4. pii: S1470-2045(16)30562.
    PubMed     Text format     Abstract available


    October 2016
  18. GOMEZ DR, Blumenschein GR Jr, Lee JJ, Hernandez M, et al
    Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.
    Lancet Oncol. 2016 Oct 24. pii: S1470-2045(16)30532.
    PubMed     Text format     Abstract available


  19. GOSS G, Tsai CM, Shepherd FA, Bazhenova L, et al
    Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
    Lancet Oncol. 2016 Oct 14. pii: S1470-2045(16)30508.
    PubMed     Text format     Abstract available


  20. LANGER CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, et al
    Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Lancet Oncol. 2016 Oct 10. pii: S1470-2045(16)30498.
    PubMed     Text format     Abstract available


  21. LE PECHOUX C
    PCI in resected small-cell lung cancer - Author's reply.
    Lancet Oncol. 2016;17:e416.
    PubMed     Text format    


  22. KNISELY J, Sharma R, Goenka A, Halthore A, et al
    PCI in resected small-cell lung cancer.
    Lancet Oncol. 2016;17:e415.
    PubMed     Text format    


    September 2016
  23. UMEWENI N, Knight H, McVeigh G
    NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer.
    Lancet Oncol. 2016 Sep 27. pii: S1470-2045(16)30488.
    PubMed     Text format    


  24. WALLINGTON M, Saxon EB, Bomb M, Smittenaar R, et al
    30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study.
    Lancet Oncol. 2016;17:1203-16.
    PubMed     Text format     Abstract available


    August 2016
  25. BURKI TK
    Predicting lung cancer prognosis using machine learning.
    Lancet Oncol. 2016 Aug 25. pii: S1470-2045(16)30436.
    PubMed     Text format    


  26. HALL CJ, Umeweni N, Knight H, Smith L, et al
    NICE guidance on ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer.
    Lancet Oncol. 2016 Aug 23. pii: S1470-2045(16)30435.
    PubMed     Text format    


  27. TAN WL, Jain A, Takano A, Newell EW, et al
    Novel therapeutic targets on the horizon for lung cancer.
    Lancet Oncol. 2016;17:e347-62.
    PubMed     Text format     Abstract available


  28. LICHT PB, Andersen C, Dan Jorgensen O, Bendixen M, et al
    Quality of life after video-assisted surgery for lung cancer - Author's reply.
    Lancet Oncol. 2016;17:e318-9.
    PubMed     Text format    


  29. NAKAZAWA S, Shimizu K, Nagashima T, Mogi A, et al
    Quality of life after video-assisted surgery for lung cancer.
    Lancet Oncol. 2016;17:e318.
    PubMed     Text format    


  30. THE VIOLET TRIALISTS CORRESPON
    Quality of life after video-assisted surgery for lung cancer.
    Lancet Oncol. 2016;17:e317.
    PubMed     Text format    


  31. VERONESI G, Novellis P, Park B
    Quality of life after video-assisted surgery for lung cancer.
    Lancet Oncol. 2016;17:e316-7.
    PubMed     Text format    


  32. MEHRAN RJ, Roth JA
    Quality of life after video-assisted surgery for lung cancer.
    Lancet Oncol. 2016;17:e315-6.
    PubMed     Text format    


    July 2016
  33. PECHOUX CL, Sun A, Slotman BJ, De Ruysscher D, et al
    Prophylactic cranial irradiation for patients with lung cancer.
    Lancet Oncol. 2016;17:e277-93.
    PubMed     Text format     Abstract available


    June 2016
  34. GOTO K, Ohe Y, Shibata T, Seto T, et al
    Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)30104.
    PubMed     Text format     Abstract available


  35. KALEMKERIAN GP
    Combination chemotherapy for relapsed small-cell lung cancer.
    Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)30160.
    PubMed     Text format    


  36. BALDWIN DR, Devaraj A
    Lung cancer risk in new pulmonary nodules: implications for CT screening and nodule management.
    Lancet Oncol. 2016 Jun 6. pii: S1470-2045(16)30134.
    PubMed     Text format    


  37. WALTER JE, Heuvelmans MA, de Jong PA, Vliegenthart R, et al
    Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial.
    Lancet Oncol. 2016 Jun 6. pii: S1470-2045(16)30069.
    PubMed     Text format     Abstract available


  38. ANTONIA SJ, Lopez-Martin JA, Bendell J, Ott PA, et al
    Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
    Lancet Oncol. 2016 Jun 3. pii: S1470-2045(16)30098.
    PubMed     Text format     Abstract available


  39. LI Y, Wu YL
    Immunotherapy for small-cell lung cancer.
    Lancet Oncol. 2016 Jun 3. pii: S1470-2045(16)30159.
    PubMed     Text format    


  40. GOLDBERG SB, Gettinger SN, Mahajan A, Chiang AC, et al
    Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
    Lancet Oncol. 2016 Jun 3. pii: S1470-2045(16)30053.
    PubMed     Text format     Abstract available


  41. PLANCHARD D, Besse B, Groen HJ, Souquet PJ, et al
    Dabrafenib plus trametinib in patients with previously treated BRAF-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
    Lancet Oncol. 2016 Jun 3. pii: S1470-2045(16)30146.
    PubMed     Text format     Abstract available


    May 2016
  42. BENDIXEN M, Jorgensen OD, Kronborg C, Andersen C, et al
    Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial.
    Lancet Oncol. 2016 May 6. pii: S1470-2045(16)00173.
    PubMed     Text format     Abstract available


    April 2016
  43. VANSTEENKISTE JF, Cho BC, Vanakesa T, De Pas T, et al
    Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2016 Apr 27. pii: S1470-2045(16)00099.
    PubMed     Text format     Abstract available


  44. QUOIX E
    Post-operative survival of patients with lung cancer.
    Lancet Oncol. 2016 Apr 27. pii: S1470-2045(16)30031.
    PubMed     Text format    


  45. PARK K, Tan EH, O'Byrne K, Zhang L, et al
    Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
    Lancet Oncol. 2016 Apr 12. pii: S1470-2045(16)30033.
    PubMed     Text format     Abstract available


  46. PLANCHARD D, Kim TM, Mazieres J, Quoix E, et al
    Dabrafenib in patients with BRAF-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
    Lancet Oncol. 2016 Apr 11. pii: S1470-2045(16)00077.
    PubMed     Text format     Abstract available


    March 2016
  47. FIELD JK, Duffy SW
    Lung cancer CT screening: is annual screening necessary?
    Lancet Oncol. 2016 Mar 18. pii: S1470-2045(16)00079.
    PubMed     Text format    


  48. PATZ EF JR, Greco E, Gatsonis C, Pinsky P, et al
    Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial.
    Lancet Oncol. 2016 Mar 18. pii: S1470-2045(15)00621.
    PubMed     Text format     Abstract available


  49. KIM DW, Mehra R, Tan DS, Felip E, et al
    Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
    Lancet Oncol. 2016 Mar 10. pii: S1470-2045(15)00614.
    PubMed     Text format     Abstract available


  50. BURKI TK
    Counting the cost of end-of-life cancer care.
    Lancet Oncol. 2016;17:e91.
    PubMed     Text format    


  51. GARON EB
    The race for combined checkpoint inhibition in NSCLC.
    Lancet Oncol. 2016;17:259-60.
    PubMed     Text format    


    February 2016
  52. TEMEL JS, Abernethy AP, Currow DC, Friend J, et al
    Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.
    Lancet Oncol. 2016 Feb 19. pii: S1470-2045(15)00558.
    PubMed     Text format     Abstract available


  53. ANTONIA S, Goldberg SB, Balmanoukian A, Chaft JE, et al
    Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
    Lancet Oncol. 2016 Feb 5. pii: S1470-2045(15)00544.
    PubMed     Text format     Abstract available


  54. CHANG JY, Senan S, Smit EF, Roth JA, et al
    Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2016;17:e42-3.
    PubMed     Text format    


  55. KATZ MS, Husain ZA
    Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer.
    Lancet Oncol. 2016;17:e41-2.
    PubMed     Text format    


  56. RIESTERER O, Weder W, Stahel R
    Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power? - Authors' reply.
    Lancet Oncol. 2016;17:e44-5.
    PubMed     Text format    


  57. RIMNER A, Simone CB 2nd, Zauderer MG, Cengel KA, et al
    Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?
    Lancet Oncol. 2016;17:e43-4.
    PubMed     Text format    


  58. HARDING E
    The Lake.
    Lancet Oncol. 2016;17:151.
    PubMed     Text format    


  59. BAKER H
    Familial risk in patients with carcinoma of unknown primary.
    Lancet Oncol. 2016;17:e48.
    PubMed     Text format    


  60. JASSEM J
    Alectinib in crizotinib-resistant, ALK-positive NSCLC.
    Lancet Oncol. 2016;17:134-5.
    PubMed     Text format    


    December 2015
  61. QUOIX E, Lena H, Losonczy G, Forget F, et al
    TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
    Lancet Oncol. 2015 Dec 22. pii: S1470-2045(15)00483.
    PubMed     Text format     Abstract available


  62. BUTTS CA, Sangha R
    TIME for a successful cancer vaccine in NSCLC?
    Lancet Oncol. 2015 Dec 22. pii: S1470-2045(15)00554.
    PubMed     Text format    


  63. SHAW AT, Gandhi L, Gadgeel S, Riely GJ, et al
    Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
    Lancet Oncol. 2015 Dec 18. pii: S1470-2045(15)00488.
    PubMed     Text format     Abstract available


  64. BROWER V
    Afatinib and chemotherapy in non-small-cell lung cancer.
    Lancet Oncol. 2015 Dec 17. pii: S1470-2045(15)00609.
    PubMed     Text format    


    October 2015
  65. FUSI A, Festino L, Botti G, Masucci G, et al
    PD-L1 expression as a potential predictive biomarker.
    Lancet Oncol. 2015;16:1285-7.
    PubMed     Text format    


    September 2015
  66. VASSAL G, Blanc P, Copland C, Pearson A, et al
    Will the revised class waiver list make it?
    Lancet Oncol. 2015;16:e425-6.
    PubMed     Text format    


  67. RICE D, Sepesi B, Heymach J, Swisher S, et al
    SABR vs surgery for NSCLC in the media.
    Lancet Oncol. 2015;16:e422.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: